ADEL K EL-NAGGAR to Paclitaxel
This is a "connection" page, showing publications ADEL K EL-NAGGAR has written about Paclitaxel.
Connection Strength
0.200
-
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck. 2009 May; 31(5):625-34.
Score: 0.052
-
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. 2005 May 01; 65(9):3883-93.
Score: 0.039
-
Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck. 2012 Sep; 34(9):1255-62.
Score: 0.015
-
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
Score: 0.014
-
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila). 2009 Sep; 2(9):823-9.
Score: 0.013
-
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82.
Score: 0.013
-
Endodermal sinus tumor of the paranasal sinuses. Head Neck. 2008 Apr; 30(4):539-43.
Score: 0.012
-
Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther. 2006 Nov; 5(11):2696-705.
Score: 0.011
-
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3425-34.
Score: 0.011
-
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx. Am J Clin Oncol. 2005 Aug; 28(4):385-92.
Score: 0.010
-
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8594-602.
Score: 0.010